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Oxidized LDL activates PAI-1 transcription through autocrine
activation of TGF-b signaling in mesangial cells
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Oxidized LDL activates PAI-1 transcription through autocrine
activation of TGF-b signaling in mesangial cells.
Background. Lipid abnormalities and oxidative stress may be
involved in the development of glomerulosclerosis. Plasmino-
gen activator inhibitor-1 (PAI-1) is a component of extracellular
matrix (ECM) and target gene of transforming growth factor-b
(TGF-b). Smad proteins play a key role in TGF-b signaling, and
Smad binding CAGA boxes are present in the PAI-1 promoter.
This study examined whether oxidized low-density lipoprotein
(Ox-LDL) activates PAI-1 transcription in human mesangial
cells, mediated by increased Smad/DNA interactions.
Methods. Quiescent HMC were incubated with 50 lg/mL of
Cu++-catalyzed Ox-LDL for 15 minutes to 4 hours, and the
effects of Ox-LDL on TGF-b1 and PAI-1 mRNA expression,
PAI-1 promoter activity, and DNA binding activity of Smad
proteins were examined.
Results. Ox-LDL induced TGF-b1 and PAI-1 mRNA ex-
pression. Ox-LDL increased the transiently transfected PAI-1
promoter activity as compared with controls to 3.9-fold. Ox-
LDL–treated cells increased Smad3 protein levels two times the
control levels in the nuclei. Electrophoretic mobility shift assay
(EMSA) performed using a CAGA sequence probe and nuclear
extracts showed that Ox-LDL increased DNA/protein com-
plexes. When nuclear extracts were preincubated with 100 mo-
lar excess of unlabeled CAGA oligonucleotide or SB-431542, an
inhibitior of the TGF-b type I receptor, the formation of com-
plex was prevented. The DNA binding protein was shown to
be Smad3 by antibody supershift. Transfection of phosphoroth-
ioate CAGA oligonucleotides, which compete with the CAGA-
containing PAI-1 promoter for Smad3 binding, inhibited the
Ox-LDL–induced PAI-1 mRNA expression. Cotransfection of
phosphorothioate CAGA oligonucleotides with PAI-1 reporter
vector also blocked the Ox-LDL-induced PAI-1 promoter
activity.
Conclusion. These results suggest that Ox-LDL activates
TGF-b/Smad signaling to stimulate PAI-1 transcription in hu-
man mesangial cells. Thus, progression of glomerular disease
may be promoted by PAI-1 up-regulation in human mesangial
cells mediated by the Ox-LDL–induced TGF-b/Smad signaling
pathways.
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Lipid abnormalities in nephrosis may play a role in
the progression of original glomerular injury to progres-
sive glomerulosclerosis [1, 2]. Hypercholesterolemia is
mainly due to the increased level of low-density lipopro-
tein (LDL). LDL may be oxidatively modified in the dis-
eased human or rat glomeruli [3, 4] and in plasma from
uremic patients [5–8]. Oxidized LDL (Ox-LDL) appears
to be involved in extracellular matrix (ECM) accumu-
lation in the glomerular mesangium and the subsequent
development of glomerulosclerosis [4, 9].
The ECM can be degraded, and a distortion of the bal-
ance between ECM synthesis and turnover may result in
an abnormal ECM accumulation. Plasminogen activator
inhibitor-1 (PAI-1) is a component of the ECM and plays
an important role in regulating blood coagulation and
tissue fibrosis. LDL regulates PAI-1 secretion in bipha-
sic patterns in human mesangial cells [10]. Because incu-
bation of LDL with cultured human mesangial cells has
been shown to result in oxidative modification [9] and
vitamin E inhibited the LDL-induced PAI-1 mRNA syn-
thesis, LDL-induced PAI-1 production in human mesan-
gial cells seems to be mediated by oxidation products
[10]. Nonetheless, the effects of Ox-LDL on mesangial
cell PAI-1 synthesis have not been clearly defined.
PAI-1 gene transcription is activated by transforming
growth factor-b (TGF-b) [11–13]. Incubation of LDL
with human mesangial cells increases TGF-b expres-
sion [14]. TGF-b signals through sequential activation of
two cell surface receptor serine-threonine kinases. Upon
TGF-b binding, the constitutively active TGF-b type II
receptor associates with and phosphorylates the TGF-b
type I receptor (TGF-bIR). The TGF-bIR kinase then
phosphorylates Smad2 and Smad3 proteins [15–20]. The
phosphorylated Smads form heteromeric complexes with
Smad4, which then translocate to the nucleus. In the nu-
cleus, the Smad3-Smad4 complex can activate transcrip-
tion through direct binding to certain DNA sequences,
such as the GTCTAGAC called Smad binding element
[21] or the AG(C/A)CAGACAC called CAGA box [12],
or by association with other DNA binding proteins [22,
23]. CAGA boxes were identified within the human PAI-
1 gene promoter [12, 24, 25].
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We proposed that Ox-LDL influences PAI-1 gene
expression in human mesangial cells mediated by
TGF-b/Smad signaling pathways. To address this issue,
we examined the effects of Cu++-catalyzed Ox-LDL on
TGF-b1 and PAI-1 mRNA expression, PAI-1 promoter
activity, and DNA binding activity of Smad proteins in
human mesangial cells.
METHODS
Reagents
Monoclonal antibodies against Smad3 and Smad4 were
kindly donated by Professor Eui Yul Choi (Hallym Uni-
versity, Choon Chun, Korea). SB-431542, an inhibitior of
the TGF-bIR [26], was purchased from Tocris Cookson
Ltd. (United Kingdom). Lysophosphatidylcholine (LPC)
was obtained from Sigma Chemical Co. (St. Louis, MO,
USA). Other reagents were from sources as previously
reported [10, 27, 28].
Culture of human mesangial cells
Human mesangial cells were obtained from adult
nephrectomy specimens, as previously described [10, 29].
The culture medium was made of Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 20% fetal
calf serum, 200 mmol/L L-glutamine, and antibiotics. For
the present experiments, cells from between the fifth and
seventh passage were used.
LDL isolation and modification
Human LDL (density 1.019 to 1.063) was isolated from
the plasma of normal volunteers by the method of se-
quential ultracentrifugation, as previously described [9,
29].
Ox-LDL was prepared as previously described [9]. In
brief, LDL (1 mg/mL) was incubated with 10 lmol/L
copper sulfate in phosphate-buffered saline (PBS) for 24
hours at 37◦C. The process was arrested by an addition
of 200 lmol/L ethylenediaminetetraacetic acid (EDTA)
and 40 lmol/L butylated hydroxytoluene. This yielded an
Ox-LDL, in which thiobarbituric acid-reactive substance
content was 7 nmol malondialdehyde equivalents/mg
of protein. Prior to each experiment, LDL and Cu++-
catalyzed Ox-LDL were dialyzed against PBS and filtered
through a 0.2 lm filter.
Experimental conditions
Human mesangial cells were grown to confluency.
The cells were synchronized to quiescence in serum-free
DMEM containing 5 lg/mL insulin-transferrin-selenite
for 48 hours. After synchronization, experiments were
performed by the addition of 50 lg/mL of Cu++-catalyzed
Ox-LDL, 100 lg/mL of LDL, or 2 lg/mL LPC for a time
period varying from 15 minutes to 24 hours at 37◦C. In
certain experiments, 25 lg/mL panspecific anti-TGF-b or
5 to 10 lmol/L SB-431542, an inhibitior of the TGF-bIR,
was added to the cells with or without Ox-LDL. In a
given experiment, simultaneous control monolayers were
treated with serum-free DMEM alone.
Northern blot analysis
Isolated RNA samples were transferred onto nylon fil-
ters. The blotted membranes were incubated with the
specific [32P]-labeled cDNA probes for human PAI-1,
TGF-b1, and b-actin, as we previously described [10, 14].
The mRNA levels for TGF-b1 and PAI-1 were expressed
as a ratio of the optical density units for either TGF-b1
or PAI-1 to b-actin.
Quantification of ECM-associated PAI-1 by
enzyme-linked immunosorbent assay (ELISA)
At the end of the incubation period, medium was re-
moved. The cell monolayer was treated with 0.02 mol/L
Tris, 0.15 mol/L NaCl, at pH 7.4, containing 0.5% Triton
X-100 as described previously [10]. After incubation for
45 minutes, the resulting cell extract was removed. ECM-
associated PAI-1 was then brought into solution by the
addition of 1 lg/mL of tissue-type plasminogen activa-
tor and incubated for 2 hours at 37◦C. A quantitative
measurement of PAI-1 antigen was carried out utilizing
ELISA kits (Biopool, Umea, Sweden) according to the
manufacturer’s instructions.
Western blot analysis
Nuclear extracts were electrophoretically resolved us-
ing a 10% polyacrylamide gel in a sodium dodecyl
sulfate (SDS) buffer and then transferred onto nitrocel-
lulose membranes as previously described [9]. The blots
were incubated in blocking solution for 1 hour and in-
cubated with rabbit anti-Smad3 antibody (Zymed Lab.
Inc., San Francisco, CA, USA) at 4◦C overnight. Bound
primary antibody was visualized after incubation with
horseradish peroxidase-conjugated secondary antibody
using an enhanced chemiluminescence (ECL) system
kit (Amersham, Arlington Heights, IL, USA). To assess
the equality of protein loading, the membrane was re-
probed with rabbit anti-cyclic adenosine monophosphate
(cAMP)-responsive element binding protein-1 (CREB-
1) antibody (Santa Cruz Biotechnologies, Santa Cruz,
CA, USA) in a dilution of 1:1000.
Plasmid constructs
PAI-1 reporter vectors (740PAI-1-LUC) were gen-
erated using pGL3 basic plasmid (Promega, Madison,
WI, USA) containing firefly luciferase coding sequence.
The −740 to +44 segment of the human PAI-1
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promoter was amplified by polymerase chain reac-
tion (PCR) from human blood genomic DNA. We
used −800 to +220 data base for human PAI-1 gene
[30] to make primers for PCR, and their sequences
were 5′-TTG-AGC-TCG-CCA-GAC-AAG-GTT-GTT-
GAC-3′ and 5′-CGA-GAT-CTG-TCT-TCT-TGA-CAG-
CGC-TCT-TGG-3′. PCR was performed at 95◦C, 53.5◦C,
and 72◦C for 1 minute, 1 minute, and 1 12 minutes, respec-
tively, for 30 cycles. PCR products were purified, checked
by sequencing, and digested with SacI and BglII. These
were cloned into pGL3-basic vector between BgIII (po-
sition +44) and SacI (position −740) sites.
Preparation of CAGA, mutant CAGA and
phosphorothioate CAGA oligonucleotides
The sequence of the double stranded CAGA oligonu-
cleotides was 5′-TCG-AGA-GCC-AGA-CAA-AAA-
GCC-AGA-CAT-TTA-GCC-AGA-CAC-3′ and its
complementary strand [12]. The sequence of the mutant
CAGA oligonucleotides was 5′-TCG-AGA-GCT-ACA-
TAA-AAA-GCT-ACA-TAT-TTA-GCT-ACA-TAC-3′
and its complementary strand [12].
Double-stranded phosphorothioate oligonucleotides
could bind sequence-specific DNA-binding proteins and
interfere with eukaryotic transcription [31]. Thus, phos-
phrothioate CAGA oligonucleotides may compete with
the CAGA-containing PAI-1 promoter for Smad3 bind-
ing. In this respect, phosphorothioate CAGA oligonu-
cleotides were prepared by attaching phosphorothioate
to each end of CAGA oligonucleotides.
Transfection and luciferase assays
Cells were grown in 6-well plates to 80% conflu-
ence. The cells were transfected with 2 lg of DNA
[1.5 lg of pGL3-PAI-1 construct and 0.5 lg of plasmid
cytomelagovirus (CpCMV)-b-galactosidase (b-gal)] or
0.6 lg of mutant CAGA or phosphorothioate CAGA
oligodeoxynucleotide mixed with Lipofectamine accord-
ing to the manufacturer’s instructions. After 6 hours of
transfection, cells were serum starved for 8 hours before
incubation with Ox-LDL or LDL for 1 to 24 hours. Then
cells were lysed on ice in 100 mmol/L KH2PO4, pH 7.9,
and 0.5% Triton X-100 and centrifuged. Luciferase and b-
gal assays were performed with reagents from Promega.
Luciferase activity was normalized to b-gal activity.
Preparation of nuclear extracts
Nuclear extracts were prepared as previously described
by Schreiber et al [32]. Briefly, the cells were washed with
Tris-buffered saline, centrifuged and resuspended in 400
lL cold buffer A [10 mmol/L Hepes, pH 7.9, 10 mmol/L
KCl, 0.1 mmol/L EDTA, 0.1 mmol/L ethyleneglycol
tetraacetate (EGTA), 1 mmol/L dithiothreitol (DTT),
and 0.5 mmol/L phenylmethylsulfonyl fluoride (PMSF)].
After a 15-minute incubation on ice, 25 lL of a 10% solu-
tion of nonionic detergent Nonidet NP-40 was added. Af-
ter a centrifugation, the nuclear pellet was resuspended
in 50 lL ice-cold buffer B (20 mmol/L Hepes, pH 7.9,
0.4 mol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1
mmol/L DTT, and 1 mmol/L PMSF) and the tube was
vigorously rocked at 4◦C for 15 minutes on a shaking
platform. The nuclear extracts were centrifuged and the
supernatant was frozen in aliquots. Protein content was
measured using bicinchoninic acid with bovine serum al-
bumin (BSA) as a standard.
Electrophoretic mobility shift assay (EMSA)
CAGA oligonucleotides described above were end-
labeled with [c-32P]-adenosine triphosphate (ATP) using
the T4 polynucleotide kinase. Five micrograms of nuclear
extracts were incubated for 30 minutes at 4◦C with 40,000
cpm of [32P]-labeled probes in 10 mmol/L Hepes, pH 7.9,
5% glycerol, 0.1 mmol/L EDTA, 1 mmol/L DTT, and 1
lg of poly(deoxyinosin-deoxycytosin). The DNA-protein
complexes were separated on a 5% polyacrylamide gel in
0.5 × Tris-borate-EDTA buffer and visualized by autora-
diography.
For competition and supershift assays, nuclear extracts
were preincubated with a 100-fold molar excess of unla-
beled CAGA oligonucleotides or 10 lL of mouse mon-
oclonal anti-Smad3 or anti-Smad4 for 30 minutes or
overnight before addition of the labeled probe.
Statistics
Results were expressed as mean ± SD of three sepa-
rate experiments. Results were analyzed by the two-way
analysis of variance (ANOVA) for three groups or by
Wilcoxon’s rank sum test between two groups. A P value
of less than 0.05 was considered significant.
RESULTS
Ox-LDL stimulates TGF-b1 and PAI-1
mRNA expression
Starting 15 minutes after incubation with human
mesangial cells, Ox-LDL at concentration of 50 lg/mL
stimulated mRNA expression of TGF-b1; expression re-
mained high until hour 4 (Fig. 1). Ox-LDL also sig-
nificantly increased 2.4 kb PAI-1 mRNA levels up to
1.9 times the control value starting 30 min until hour 4
(Fig. 1). When cells were treated with SB-431542, an in-
hibitior of the TGF-bIR, 1 hour before Ox-LDL adminis-
tration, the expected increase in PAI-1 mRNA level was
significantly decreased. There was no significant differ-
ence in PAI-1 mRNA levels between control cells with or
without SB-431542 treatment (Fig. 2).
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Fig. 1. Northern blot analysis of transforming growth factor-b1 (TGF-
b1) and plasminogen activator inhibitor-1 (PAI-1) mRNA in human
mesangial cells. Cells were incubated with 50 lg/mL of oxidized low-
density lipoprotein (Ox-LDL) for 15 minutes (lane 2), 30 minutes (lane
3), 1 hour (lane 4) and 4 hours (lane 5) or Dulbecco’s modified Eagle’s
medium (DMEM) alone (lane 1). The blots were hybridized with [32P]-
labeled cDNAs for TGF-b1 (A), PAI-1 (B), and b-actin (C). (D) Quan-
titative expression of TGF-b1 and 2.4 kb PAI-1 mRNA abundance after
correction for b-actin signal. The mRNA levels of Ox-LDL–treated hu-
man mesangial cells are expressed as percentage increases above the
mRNA levels of DMEM-treated controls. Values are means ± SD of
three separate experiments. ∗P < 0.05 vs. DMEM-treated controls.
Ox-LDL also induced a 1.3-fold increase in the ECM-
associated PAI-1 antigen 4 hours after incubation with hu-
man mesangial cells, while pretreatment with SB-431542
significantly reduced the expected increase in PAI-1 anti-
gen levels (Fig. 3).
Ox-LDL increases PAI-1 gene promoter activity
In cells transfected with 740PAI-1-LUC construct, con-
taining the sequence from −740 to +44 of the human
PAI-1 promoter in front of the luciferase reporter gene,
Ox-LDL treatment for 1 hour resulted in almost 3.9-fold
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Fig. 2. Northern blot analysis from cells treated for 4 hours with Dul-
becco’s modified Eagle’s medium (DMEM) alone (control) (lane 1)
or 50 lg/mL oxidized low-density lipoprotein (Ox-LDL) (lane 2) or
both Ox-LDL and SB-431542 (Ox-LDL + SB) (lane 3) or SB-431542
alone (SB) (lane 4). The blots were hybridized with [32P]-labeled cDNA
for plasminogen activator inhibitor-1 (PAI-1) (A) and b-actin (B). (C)
quantitative expression of 2.4 kb PAI-1 mRNA abundance after correc-
tion for b-actin signal. The mRNA levels of Ox-LDL–treated human
mesangial cells or SB-431542–treated control cells are expressed as per-
centage increases above the mRNA levels of DMEM-treated controls.
Values are means ± SD of three separate experiments. ∗P < 0.05 vs. all
other groups.
increase in luciferase activity as compared with control
cells. When cells were treated with SB-431542 1 hour be-
fore Ox-LDL administration, the expected increase in
PAI-1 promoter luciferase activity was significantly de-
creased. Treatment of 100 lg/mL LDL for 24 hours also
increased luciferase activity as compared with control
cells. However, the luciferase activity induced by LDL
was significantly lower than that by Ox-LDL (Fig. 4).
Ox-LDL increases nuclear Smad3 expression in human
mesangial cells
Incubation of human mesangial cells with 50 lg/mL of
Ox-LDL for 4 hours increased Smad3 expression to two
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Fig. 3. Effects of oxidized low-density lipoprotein (Ox-LDL) on ex-
tracellular matrix (ECM)-associated plasminogen activator inhibitor-1
(PAI-1) antigen levels. Human mesangial cells were incubated with Dul-
becco’s modified Eagle’s medium (DMEM) alone (control), 50 lg/mL
Ox-LDL, both Ox-LDL and SB-431542 (Ox-LDL + SB), or SB-431542
alone (SB) for 4 hours. ECM-associated PAI-1 was brought into solu-
tion by the addition of tissue plasminogen activator, and PAI-1 antigen
was measured by enzyme-linked immunosorbent assay (ELISA). Val-
ues are means ± SD of three separate experiments. ∗P < 0.05 vs. all
other groups.
times the control level in the nuclei as shown by Western
blotting (Fig. 5).
Anti-TGF-b attenuates Ox-LDL–induced increases in
nuclear Smad3 expression
When cells were incubated with panspecific anti-TGF-
b antibody (25 lg/mL) along with Ox-LDL for 4 hours,
the expected increase in Smad3 expression was signif-
icantly reduced. However, the same concentration of
control rabbit IgG had no effect on Ox-LDL–induced
increase in Smad3 levels. As expected, Smad3 levels in
anti-TGF-b–treated cells were not significantly different
from controls (Fig. 6).
Ox-LDL or its active components increase the
DNA/protein binding complexes
An EMSA was performed using an oligonucleotide
containing three CAGA boxes as a probe. Nuclear
extracts were prepared from human mesangial cells
exposed to DMEM, 100 lg/mL LDL, 2 lg/mL LPC, or 50
lg/mL of Ox-LDL for 4 hours. One DNA/protein com-
plex was detected, and its intensity significantly increased
with LDL-, LPC-, or Ox-LDL–treated cells than the con-
trol cells (Fig. 7, lanes 2 to 5).
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Fig. 4. Stimulation of plasminogen activator inhibitor-1 (PAI-1) pro-
moter activity by oxidized low-density lipoprotein (Ox-LDL) or LDL.
Cells were transiently transfected with DNA containing the PAI-1 re-
porter vector (740PAI-1-LUC) and plasmid cytomegalovirus (pCMV)-
b-galactosidase (b-gal), or the empty expression vector (pGL3). The
740PAI-1-LUC transfected cells were treated with Dulbecco’s modi-
fied Eagle’s medium (DMEM) alone (control), 100 lg/mL LDL for
24 hours (LDL), 50 lg/mL Ox-LDL for 1 hour without (Ox-LDL) or
with pretreatment of SB-431542 (Ox-LDL + SB), or SB-431542 alone
(SB). Luciferase activity was normalized to b-gal activity. The results
are expressed as fold-stimulation by Ox-LDL or LDL compared with
DMEM-treated control cells. Values are means ± SD of three separate
experiments. ∗P < 0.05 vs. controls; ∗∗P < 0.05 vs. all other groups.
Smad3 protein is present in the DNA/protein complex
and binds to the CAGA sequences
To further demonstrate the presence of Smad3 or
Smad4 in the DNA/protein complex, nuclear extracts
from Ox-LDL–treated cells were preincubated with mon-
oclonal antibody against Smad3 or Smad4 before mix-
ing with the labeled probe. Addition of anti-Smad3
resulted in a slower migrating complex, while forma-
tion of DNA/protein complex was completely inhibited
(Fig. 7, lane 7). With anti-Smad4, DNA/protein complex
formation was also completely inhibited. However, no su-
pershifted complex was detected (Fig. 7, lane 8). Normal
mouse IgG, however, did not affect formation of these
complexes (Fig. 7, lane 6).
To determine whether Smad proteins interact with
CAGA sequences, competition experiments were per-
formed with 100 molar excess of unlabeled CAGA
oligonucleotides. When nuclear extracts were preincu-
bated with unlabeled probe, the formation of complex
was completely prevented (Fig. 8, lane 4). The addition
of SB-431542 1 hour before Ox-LDL administration also
inhibited the formation of DNA/protein binding com-
plexes (Fig. 8, lane 3).
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Fig. 5. Western blot analysis of Smad3 in nuclear extracts from cells
treated with Dulbeco’s modified Eagle’s medium (DMEM) alone (lane
1) or 50 lg/mL oxidized low-density lipoprotein (Ox-LDL) (lane 2)
for 4 hours. Membranes were probed with anti-Smad3 (A) and anti-
cyclic adenosine monophosphate (cAMP)-responsive element binding
protein-1 (CREB-1) (B). (C) Quantitative expression of Smad3 after
correction for CREB-1 signal. Values in Ox-LDL represent relative ra-
tios compared with Smad3 density in control cells, assigned an arbitrary
value of 1. Values are mean ± SD of three comparable experiments.
∗P < 0.05 vs. controls.
Ox-LDL increases PAI-1 transcription mediated by the
CAGA sequences
To examine whether Ox-LDL–induced PAI-1 tran-
scription is mediated through Smad-binding CAGA
sequences, phosphorothioate CAGA oligonucleotides
or mutant CAGA oligonucleotides were transfected
into human mesangial cells. Transfection of cells with
[32P]-labeled phosphorothioate CAGA oligonucleotides
resulted in strong radioactivity confirming their suc-
cessful transfection. Upon Ox-LDL treatment, phospho-
rothioate CAGA oligonucleotide-transfected cells exhib-
ited significantly reduced PAI-1 mRNA expression as
compared with nontransfected cells or mutant CAGA
oligonucleotide-transfected cells (Fig. 9). Luciferase ac-
tivity upon Ox-LDL treatment was significantly de-
creased in cells cotransfected with phosphorothioate
CAGA oligonucleotide and 740PAI-1-LUC as com-
pared with those transfected with 740PAI-1-LUC alone
(Fig. 10).
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Fig. 6. Western blot analysis of Smad3 in nuclear extracts from cells
treated for 4 hours with Dulbecco’s modified Eagle’s medium (DMEM)
alone (lane 1), with addition of 50 lg/mL oxidized low-density lipopro-
tein (Ox-LDL) (OL) (lane 2), both Ox-LDL and anti-transforming
growth factor-b (TGF-b) (OL + anti-Tb) (lane 3), both Ox-LDL and
IgG (OL + IgG) (lane 4), or anti-TGF-b alone (anti-Tb) (lane 5).
Membranes were probed with anti-Smad3 (A) and anti-cyclic adeno-
sine monophosphate-1 (cAMP)-responsive element binding protein
(CREB-1) (B). (C) Quantitative expression of Smad3 after correction
for CREB-1 signal. Values in Ox-LDL– or TGF-b–treated cells repre-
sent relative ratios compared with Smad3 density in control cells, as-
signed an arbitrary value of 1. Values are means ± SD of three separate
experiments. ∗P < 0.05 vs. control, OL + anti-Tb , or anti-Tb .
DISCUSSION
This study shows that, to the best of our knowledge
for the first time, Ox-LDL increases TGF-b1 and PAI-1
mRNA expression, nuclear Smad3 protein levels, PAI-
1 gene promoter activity, and DNA binding activity of
Smad3 in human mesangial cells. It also shows that the
Ox-LDL–induced PAI-1 gene up-regulation is mediated
through Smad3-binding CAGA sequence in the PAI-1
promoter.
We found that treatment of mesangial cells with Ox-
LDL increased steady-state TGF-b1 and PAI-1 mRNA
levels after 30 minutes. The current observation with Ox-
LDL–induced TGF-b1 mRNA overexpression is similar
to our previous study showing native LDL-induced TGF-
b1 mRNA expression [14]. However, in the case of PAI-1
mRNA overexpression, incubation time with LDL was
much longer than Ox-LDL [10], possibly because cell-
mediated LDL oxidation is milder than Cu++-catalyzed
one [9]. Similar to our results, Ox-LDL stimulated PAI-1
mRNA expression after 4 hours of incubation in
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Fig. 7. Electrophoretic motility shift assay
(EMSA) using an oligonucleotide containing
three CAGA boxes as a probe. Nuclear ex-
tracts were prepared from human mesangial
cells exposed to Dulbecco’s modified Eagle’s
medium (DMEM) (lane 2), 100 lg/mL low-
density lipoprotein (LDL) (lane 3), 2 lg/mL
lysophosphatidylcholine (LPC) (lane 4), or
50 lg/mL of Ox-LDL (lanes 5 to 8) for 4
hours. DNA/protein complexes are detected
(arrow, top parts of gels). Anti-Smad3 (lane
7) or anti-Smad4 (lane 8) antibody was prein-
cubated with nuclear extracts before mixing
with labeled probe. The supershifted complex
is indicated (arrowhead). Addition of normal
mouse IgG did not affect formation of these
complexes (lane 6).
vascular smooth muscle cells, whereas the effects of LDL
on PAI-1 production were more variable [33]. In con-
trast to our previous studies showing an LDL-induced
increase in TGF-b protein secretion and bioactivity in
human mesangial cells [14], those were not measured in
the present study. Thus, showing an Ox-LDL-induced in-
crease in TGF-b1 mRNA levels is suggestive of increased
expression, but is not confirmatory that this is the mech-
anism of action.
In this study, incubation of Ox-LDL with human
mesangial cells increased the nuclear Smad3 protein
levels as compared with controls, suggesting that Ox-
LDL can activate Smad signaling in mesangial cells with
translocation of Smad complexes into nuclei. Further-
more, anti-TGF-b significantly attenuated the Ox-LDL–
induced increases in nuclear Smad3 expression, suggest-
ing that Ox-LDL stimulates Smad pathway through the
induction of TGF-b signaling pathway.
Our EMSA results demonstrate that incubation of Ox-
LDL, LPC, or LDL with human mesangial cells signifi-
cantly increased the intensity of DNA/protein (binding)
complexes as compared with controls. Oxidation of LDL,
either by Cu++ or cultured cells, is associated with forma-
tion of lipid peroxides, LPC, and other reactive oxygen
intermediates [34]. Thus, these active components of Ox-
LDL might be involved in the increased DNA/protein
binding complex formation in human mesangial cells pos-
sibly via TGF-b/Smad signaling pathway.
We also found that the CAGA sequence binding pro-
tein was Smad3 by antibody supershift, in agreement with
the report of Dennler et al [12] using other cells. Fur-
thermore, formation of DNA/protein complex was in-
hibited with anti-Smad4, suggesting that Smad4 can also
bind to the CAGA sequences. In the present study, su-
pershifted complex was not detected with anti-Smad4,
while Dennler et al [12] observed partly supershifted
one.
We also observed that SB-431542, an inhibitior of
the TGF-bIR, inhibited the Ox-LDL–induced enhanced
nuclear protein binding activity to DNA, PAI-1 pro-
moter activity, and PAI-1 synthesis in human mesangial
cells. Because TGF-bIR phosphorylates Smad proteins
[18–20], SB-431542 could inhibit Ox-LDL–induced in-
tracellular signaling to the nucleus, Smad/DNA inter-
actions and subsequent PAI-1 synthesis. In support of
our observations, SB-431542 inhibited TGF-b1–induced
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Fig. 8. Electrophoretic motility shift assay (EMSA) using a labeled
CAGA sequence probe and nuclear extracts from cells treated with
Dulbecco’s modified Eagle’s medium (DMEM) (lane 1) or 50 lg/mL
oxidized low-density lipoprotein (Ox-LDL) (lanes 2 to 4) for 4 hours.
DNA/protein complexes are identified (arrow, top parts of gels). For
competition experiments, nuclear extracts were preincubated with a
100-fold molar excess of unlabeled CAGA oligonucleotide for 30 min-
utes before addition of labeled probe (lane 4). To examine the effects
of transforming growth factor-b (TGF-b) type I receptor, SB-431542
was added 1 hour before Ox-LDL administration (lane 3).
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Fig. 9. Northern blot analysis of plasminogen activator inhibitor-1
(PAI-1) mRNA in human mesangial cells without (lanes 1 and 2) or with
transfection of phosphorothioate CAGA oligonucleotide (P-CAGA)
(lanes 3 and 5) or mutant CAGA oligonucleotide (M-CAGA) (lane
4). Cells were incubated with Dulbecco’s modified Eagle’s medium
(DMEM) (lanes 1 and 5) or 50 lg/mL of oxidized low-density lipopro-
tein (Ox-LDL) (OL) (lanes 2 to 4) for 3 hours. The blots were hybridized
with [32P]-labeled cDNAs for PAI-1 (A) and b-actin (B). (C) Quantita-
tive expression of PAI-1 mRNA abundance after correction for b-actin
signal. The mRNA levels of Ox-LDL–treated human mesangial cells
(OL, OL + P-CAGA, or OL + M-CAGA) or cells transfected with P-
CAGA are expressed as percentage increases above the mRNA levels
of DMEM-treated controls. Values are means ± SD of three separate
experiments. ∗P < 0.05 vs. controls, OL + P-CAGA, or P-CAGA.
phosphorylation of Smad3, nuclear Smad3 localization,
and ECM production in cultured renal epithelial carci-
noma cells [35].
In our study, transfection of phosphorothioate
CAGA oligonucleotide inhibited Ox-LDL–induced PAI-
1 mRNA expression. Cotransfection of the phosphoroth-
ioate CAGA oligonucleotide with the PAI-1 promoter
construct also blocked the Ox-LDL–induced luciferase
activity. These results suggest that CAGA boxes in the
PAI-1 promoter could mediate Ox-LDL–induced PAI-1
promoter activation and PAI-1 gene transcription in hu-
man mesangial cells.
In the present study, increase in Smad/DNA binding
could explain the increased PAI-1 promoter activity in-
duced by Ox-LDL. CAGA boxes themselves might be
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Fig. 10. Luciferase activity in human mesangial cells transfected with
740 plasminogen activator inhibitor-1 (PAI-1)-LUC alone [control or
oxidized low-density lipoprotein (Ox-LDL) (Ox-L)] or cotransfected
with phosphorothioate CAGA (P-CAGA oligonucleotide (Ox-L + P-
CAGA, or P-CAGA), which were then treated for 3 hours with Dul-
becco’s modified Eagle’s medium (DMEM) (control or P-CAGA) or
50 lg/mL Ox-LDL (Ox-L or Ox-L + P-CAGA). Values are mean ±
SD of three separate experiments. ∗P < 0.05 vs. all other groups.
sufficient to mediate TGF-b–transcriptional effects [12],
although Smads must cooperate with other transcription
factors to effect the transcription of a target gene [36, 37].
Ox-LDL is present in the diseased human glomeruli [3]
and in plasma from uremic patients [5–8]. Our current in
vitro study suggests that Ox-LDL induced an increase in
nuclear Smad3 that may directly bind to the CAGA box
in the PAI-1 promoter in vivo leading to transcriptional
induction of PAI-1. Up-regulation of PAI-1 expression by
Ox-LDL may be relevant to chronic progressive glomeru-
lar diseases. PAI-1 has been implicated in renal disease
as being a mediator of ECM accumulation [38] and as a
feedback mechanism to limit vascular fibrinolysis [39, 40].
Thus, persistent hypercholesterolemia and increased Ox-
LDL in chronic renal disease could lead to a mesangial
ECM accumulation and to eventual renal fibrosis.
CONCLUSION
Our results suggest that Ox-LDL activates Smad3/
DNA interactions, which, in turn, induces PAI-1 tran-
scription in human mesangial cells. Thus, progression
of glomerular injury may be promoted by PAI-1 up-
regulation mediated by the Ox-LDL–induced TGF-b/
Smad signaling.
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